Furthermore, when evaluating patients with persistent abdominal symptoms and potential overlap of DGBI and IBD, the initial step involves employing non-invasive markers such as C-reactive protein (CRP) and fecal calprotectin to rule out objective inflammation. This evidence concerns the gene CRP and irritable bowel syndrome.